Niva Bupa Health Insurance Company Analyst Review May 2026

This Niva Bupa Health Insurance Company analyst review for May 2026 covers all critical data investors need for NIVABUPA at Rs 83.96. Niva Bupa Health Insurance is a leading health insurance company. This Niva Bupa Health Insurance Company analyst review analyses technical levels, business fundamentals, valuation, and key risks for NIVABUPA through FY27.

Click Here – Get Free Investment Predictions

Niva Bupa Health Insurance Company Analyst Review: Company Snapshot May 2026

Niva Bupa (formerly Max Bupa) provides comprehensive health insurance plans for individual, family, and corporate clients. Rising health insurance penetration and premiumisation drive growth. The table below summarises key metrics for this Niva Bupa Health Insurance Company analyst review.

Parameter	Value
NSE Ticker	NIVABUPA
Sector	Insurance – Health
CMP (May 2026)	Rs 83.96
52 Week High	Rs 100.75
52 Week Low	Rs 67.17
Market Cap	Rs 12500 Crore
Trailing P/E	NAx
Analyst Consensus Target	Rs 104.95
Bull Case Target	Rs 130.14
Bear Case Target	Rs 71.37

Analyst Insight: Niva Bupa Health Insurance Company Analyst Review for FY27

Senior Research Analyst Ankit Jaiswal flags Niva Bupa Health Insurance Company as a stock to watch in May 2026. At Rs 83.96, Ankit Jaiswal identifies key support in the Rs 68.51 to Rs 79.76 band and resistance near Rs 89.00. He suggests watching Niva Bupa Health Insurance Company for a potential move toward Rs 104.95. Ankit Jaiswal’s view in this Niva Bupa Health Insurance Company analyst review does not constitute a trade recommendation.

Technical Analysis in This Niva Bupa Health Insurance Company Analyst Review

This Niva Bupa Health Insurance Company analyst review places NIVABUPA at Rs 83.96 within its 52-week band of Rs 67.17 to Rs 100.75. The 14-day RSI, MACD signal, and volume profile are key technical inputs when evaluating NIVABUPA.

The Niva Bupa Health Insurance Company analyst review identifies support in the Rs 68.51 to Rs 79.76 range and resistance in the Rs 89.00 to Rs 94.45 zone. A sustained close above Rs 89.00 could signal momentum toward the analyst consensus target of Rs 104.95.

Screen the best stocks on the Univest Screener.

Support and Resistance in This Niva Bupa Health Insurance Company Analyst Review

• Support Zone: Rs 68.51 to Rs 79.76 – this Niva Bupa Health Insurance Company analyst review identifies this as a potential accumulation signal for NIVABUPA.
• Resistance Zone: Rs 89.00 to Rs 94.45 – the Niva Bupa Health Insurance Company analyst review flags a close above Rs 89.00 as a positive signal for NIVABUPA.
• Consensus Target: Rs 104.95 is the base-case target in this Niva Bupa Health Insurance Company analyst review.

Business Segments in This Niva Bupa Health Insurance Company Analyst Review

Retail Health Insurance (Individual and Family)

This primary segment drives revenue and margin for Niva Bupa Health Insurance Company, supporting the earnings trajectory toward Rs 104.95 in this Niva Bupa Health Insurance Company analyst review.

Group and Corporate Health Insurance

This segment adds meaningful scale to Niva Bupa Health Insurance Company’s model and is a key EPS contributor through FY27 as identified in this Niva Bupa Health Insurance Company analyst review.

New Product Innovation and Digital Distribution

This growth frontier is a potential re-rating catalyst for NIVABUPA and a key element of this Niva Bupa Health Insurance Company analyst review.

Valuation: Niva Bupa Health Insurance Company Analyst Review Bull Bear Base Case

At Rs 83.96 and P/E of NAx, this Niva Bupa Health Insurance Company analyst review sets three scenarios: bull case Rs 130.14, base case Rs 104.95, and bear case Rs 71.37.

Scenario	Target Price	Key Condition
Bull Case	Rs 130.14	Strong FY27 delivery and Insurance – Health re-rating
Base Case	Rs 104.95	Moderate growth per analyst consensus in this Niva Bupa Health Insurance Company analyst review
Bear Case	Rs 71.37	Earnings miss or macro headwinds for NIVABUPA

FY27 Outlook in This Niva Bupa Health Insurance Company Analyst Review

This Niva Bupa Health Insurance Company analyst review for FY27 is constructive provided NIVABUPA delivers on earnings expectations. Q1 FY27 results will be the first checkpoint. Investors should monitor Insurance – Health indicators, RBI policy, and FII flow trends.

Key Risks in This Niva Bupa Health Insurance Company Analyst Review

This Niva Bupa Health Insurance Company analyst review identifies four key risks for NIVABUPA: macro slowdown, input cost pressure, FII selling, and Q1 FY27 earnings disappointment.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Niva Bupa Health Insurance Company Analyst Review Verdict May 2026

This Niva Bupa Health Insurance Company analyst review concludes that NIVABUPA at Rs 83.96 presents a defined risk-reward with consensus target Rs 104.95. The 52-week range of Rs 67.17 to Rs 100.75 provides further context. Use this Niva Bupa Health Insurance Company analyst review as a research reference and consult a SEBI-registered advisor before investing in NIVABUPA.

FAQs: Niva Bupa Health Insurance Company Analyst Review 2026

What is the analyst target for Niva Bupa Health Insurance Company in 2026?

The Niva Bupa Health Insurance Company analyst review consensus target is Rs 104.95, bull case Rs 130.14, bear case Rs 71.37.

Is Niva Bupa Health Insurance Company a good buy at Rs 83.96?

At Rs 83.96 with PE NAx and target Rs 104.95, this Niva Bupa Health Insurance Company analyst review is constructive for 12-month investors. Consult a SEBI-registered advisor before acting on this Niva Bupa Health Insurance Company analyst review.

What is the 52-week high and low of Niva Bupa Health Insurance Company?

52-week high is Rs 100.75 and 52-week low is Rs 67.17. This Niva Bupa Health Insurance Company analyst review contextualises NIVABUPA at Rs 83.96 within this range.

What are the key risks for Niva Bupa Health Insurance Company?

Key risks in this Niva Bupa Health Insurance Company analyst review: macro slowdown, input cost pressure, FII selling, and competitive pressure in the Insurance – Health sector.

Where can I track live data for Niva Bupa Health Insurance Company?

Track Niva Bupa Health Insurance Company’s live price on the Univest Screener to complement this Niva Bupa Health Insurance Company analyst review with real-time data.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.